Candel Therapeutics Inc. has released a corporate presentation highlighting recent progress and key achievements in its clinical programs. The report details positive results for CAN-2409 (aglitimagene besadenovec), an off-the-shelf pan-solid tumor therapy, including favorable data from a phase 3 randomized placebo-controlled trial in localized, intermediate- to high-risk prostate cancer. Additional positive overall survival data were observed in randomized phase 2a clinical trials of CAN-2409 in both borderline resectable pancreatic cancer and therapy-resistant non-small cell lung cancer. The company also outlined a strong financial position, with cash and cash equivalents of $87.0 million as of September 30, 2025, and a term loan facility of up to $130 million established in October 2025. Precommercialization activities for CAN-2409 are underway to support a potential commercial launch following approval. Key anticipated milestones for 2025-2026 include updated clinical results in prostate cancer, non-small cell lung cancer, and recurrent high-grade glioma, as well as initiation of new phase 3 trials. You can access the full presentation through the link below.